⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 17, 2025Open Access

Supplemental Table S5 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Funda Meric‐Bernstam Martin Gutierrez Enrique Sanz‐García Diego Villa Jun Zhang Jennifer Friedmann Fengting Yan Mark A. Socinski John Sarantopoulos Luis E. Raez Quincy S. Chu Maxime Chénard-Poirier Manash S. Chatterjee Hong Ren Qi Liu Douglas A. Levine Komal Jhaveri

View Full Paper

Ask AI

Bookmark

Share

Key Points

The geometric mean plasma PK parameter values indicate drug levels in participants after treatment.
Zilovertamab vedotin was administered intravenously every three weeks to assess its pharmacokinetics.
This phase 2 study helps evaluate the drug's effectiveness in treating metastatic solid tumors.
Understanding these PK values may assist in optimizing treatment for patients with advanced solid tumors.

Implication

Phase 2 study measures plasma PK parameter values in patients with metastatic solid tumors, suggesting effective treatment monitoring.

Abstract

Supplemental Table S5. Geometric Mean Plasma PK Parameter Values in C1 Following Zilovertamab Vedotin IV Once Every 3 Wks

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Meric‐Bernstam et al. (2025) studied this question.

synapsesocial.com/papers/68d462b631b076d99fa61ada https://doi.org/10.1158/2767-9764.30146484

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Table S6 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
2Supplemental Fig S5 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
3Supplemental Fig S8 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
4Supplemental Table S1 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
5Supplemental Fig S6 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025

More related papers

Supplemental Fig S9 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
Supplemental Table S3 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025
Supplemental Fig S7 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors2025